Sintx Technologies, Inc. (NASDAQ: SINT) shares are experiencing a significant increase on the US stock charts today after the issuance of a newly granted patent. As of the last premarket check, SINT stock was surging 79.44% to trade at $5.06.
Patent Approval Strengthens Market Position
Sintx Technologies (SINT) announced that the United States Patent and Trademark Office (USPTO) has awarded the company with U.S. Patent No. 12,239,761. The patent is not only a major addition to its growing portfolio of intellectual property, but also confirms Sintx’s position as a leader in silicon nitride technology, a segment that is still advancing at a rapid pace.
Advancing Biomedical Applications
The patent focuses on modern developments in silicon nitride material synthesis, especially for biomedical applications. Silicon nitride’s antiviral, antibacterial, and biomechanical qualities have made it a popular material for next-generation medical implants, regenerative medicine, and advanced coating technologies.
Innovation in Implant Technology
Innovative techniques for combining silicon nitride with a variety of biomaterial substrates are presented by the recently patented technology. Biocompatibility and infection resistance, two critical components of medical implant function, are greatly enhanced by this development.
According to Sintx Technologies, this development will increase the application of silicon nitride in important medical domains such as dental, spinal, orthopaedic, and craniomaxillofacial implants. In order to make sure that its solutions contribute to better surgical results and longer implant lifespans, Sintx keeps improving its unique technology via continuous research and development.
Increasing the Portfolio of Intellectual Property
The only FDA-registered producer of implantable silicon nitride, Sintx Technologies, has produced a wide variety of goods, including as monolithic ceramic implants, particulate-based coatings, composite materials, and microspheres. Sintx Technologies now has 17 U.S. patents issued and 84 more applications pending globally. The business is still dedicated to growing its portfolio of intellectual property and leading the way in biomedical engineering developments.